

## CORRECTION

[View Article Online](#)  
[View Journal](#) | [View Issue](#)



Cite this: *J. Mater. Chem. B*, 2025, 13, 5967

## Correction: The design and synthesis of redox-responsive oridonin polymeric prodrug micelle formulation for effective gastric cancer therapy

Luzhou Xu,<sup>a</sup> Lei Zhu,<sup>a</sup> Kai Zheng,<sup>a</sup> Junlou Liu,<sup>b</sup> Panpan Tian,<sup>c</sup> Di Hu,<sup>b</sup> Qianqian Wang,<sup>b</sup> Qiaoyun Zuo,<sup>b</sup> Xaosong Ouyang,<sup>b</sup> Yanna Dai,<sup>b</sup> Yuxian Fu,<sup>b</sup> Xinyi Dai,<sup>b</sup> Fang Huang<sup>\*d</sup> and Jun Cheng<sup>\*ef</sup>

DOI: 10.1039/d5tb90072g

rsc.li/materials-b

Correction for 'The design and synthesis of redox-responsive oridonin polymeric prodrug micelle formulation for effective gastric cancer therapy' by Luzhou Xu *et al.*, *J. Mater. Chem. B*, 2021, **9**, 3068–3078, <https://doi.org/10.1039/D1TB00127B>.

The authors regret an error in the names of the cell lines used in this study. Specifically, the human gastric cancer cell lines employed were BGC 823 and SGC 7901, both procured from Shanghai Fuheng Biotechnology Co., Ltd.

However, the name BGC 823 was incorrectly spelled as MGC 823 in the "Cellular uptake" section, the "Cellular uptake studies" section, and the caption of Fig. 4. Additionally, in the "Cell and animals" section of the supporting information, BGC 823 was erroneously recorded as MGC 803.

The results of Short Tandem Repeat (STR) analysis conducted by the National Collection of Authenticated Cell Cultures (Shanghai, China) and Jiangsu KeyGen Biotechnology Co., Ltd (Nanjing, China) confirmed that the submitted BGC 823 cells precisely correspond to the human gastric cancer BGC 823 cells as documented in the ExPASy database.

The caption of Fig. 3 was incorrect as it referred to panel C twice, and should have read:

**Fig. 3** Redox-responsive evaluation of the P-ss-ORI and P-ORI formulations. (A)–(C) Size changes of P-ss-ORI and P-ORI after incubation at pH 7.4 (A), pH 7.4 with 10.0 mM GSH (B), or pH 5.0 (C),  $n = 3$ . (D and E) Cumulative release of ORI from P-ORI (D) or P-ss-ORI (E) in the presence of 10.0 mM or 20.0  $\mu$ M GSH, pH 7.4, and pH 5.0, respectively,  $n = 3$ .

In Fig. 4, the fluorescein used in the cell uptake is FITC, which was incorrectly labelled as Coumarin-6.

The caption of Fig. 5 was incorrect due to incorrect labelling of panels B and C, the corrected caption is shown below:

**Fig. 5** *In vitro* cytotoxicity of GC cell lines following treatment with PPM preparations. (A and C) Cell viability of BGC 823 cells after incubation with PEG-*b*-PLL-DTPA, PEG-*b*-PLL-SA, ORI, P-ss-ORI, or P-ORI ( $n = 6$ ). (B and D) Cell viability of SGC 7901 cells after culturing with PEG-*b*-PLL-DTPA, PEG-*b*-PLL-SA, ORI, P-ss-ORI, or P-ORI ( $n = 6$ ).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup> Gastroenterology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China

<sup>b</sup> The First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing, 210023, China

<sup>c</sup> Internal Medicine Department, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China

<sup>d</sup> School of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, 211199, China. E-mail: chengtianle007@163.com

<sup>e</sup> Jiangsu Hongdian Research Institute of Traditional Chinese Medicine Industry, Nanjing, 210042, China. E-mail: cj9119@sina.com

<sup>f</sup> Nanjing Zhongshan Pharmaceutical Co. Ltd, Nanjing, 210046, China

